<DOC>
	<DOCNO>NCT00003558</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . It yet know combination chemotherapy regimen effective cancer unknown primary origin . PURPOSE : Randomized phase III trial compare effectiveness two different regimen combination chemotherapy treat patient cancer unknown primary origin .</brief_summary>
	<brief_title>Chemotherapy Treating Patients With Cancer Unknown Primary Origin</brief_title>
	<detailed_description>OBJECTIVES : - Compare overall survival treatment paclitaxel , carboplatin , etoposide treatment fluorouracil leucovorin calcium patient adenocarcinoma unknown primary . - Compare response rate , progression free survival , toxicity profile , quality life two regimens patient . OUTLINE : This randomize , multicenter study . Patients stratify center presence absence liver metastasis . Patients randomly assign one two treatment arm . - Arm I : Patients receive paclitaxel IV 1 hour carboplatin IV 30 minute day 1 , oral etoposide day 1-10 . Treatment repeat every 3 week four course . - Arm II : Patients receive leucovorin calcium IV 2 hour follow fluorouracil IV 24 hour weekly 6 week . Treatment repeat every 7 week two course . Patients follow every 3 month treatment 1 year death . Quality life questionnaire complete follow-up . PROJECTED ACCRUAL : Approximately 120-140 patient accrue study within 3 year .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms , Unknown Primary</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma differentiation grade Excludes follow `` treatable '' condition : Axillary node involvement Peritonitis carcinomatosis Blastic bone metastases and/or elevate PSA Squamous cell cancer cervical inguinal presentation Poorly differentiate carcinoma Neuroendocrine tumor OR Tumors locate mediastinum , retroperitoneum , node At least one measurable metastatic site No brain meningeal metastases PATIENT CHARACTERISTICS : Age : Over 18 Performance status : ECOG 02 Hematopoietic : Leukocyte count least 4,000/mm3 Thrombocyte count least 100,000/mm3 Hepatic : Bilirubin le 1.4 mg/dL AST ALT less 3 time upper limit normal No cirrhosis liver Renal : Creatinine le 1.7 mg/dL Cardiovascular : At least 3 month since myocardial infarction No congestive heart failure , tachydysrhythmia , unstable angina pectoris Other : Not pregnant nursing Negative pregnancy test No active infection No serious illness medical condition No current prior malignancy except nonmelanomatous skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : At least 4 week since prior radiotherapy ( great 25 % bone marrow ) Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2003</verification_date>
	<keyword>adenocarcinoma unknown primary</keyword>
	<keyword>newly diagnose carcinoma unknown primary</keyword>
</DOC>